Medicine composition containing insulin sensibilizer and B-family vatamines

A technology of insulin sensitizer and B vitamins, which is applied in the directions of drug combination, medical preparations containing active ingredients, and pill delivery, etc., can solve the problems of the prevention of complications and the unsatisfactory overall treatment effect of diabetic patients. , to achieve the effect of reducing medical costs, convenient medication, and improving patient compliance

Active Publication Date: 2007-04-04
SHENZHEN AUSA PHARM CO LTD +2
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, thiazolidinediones are not satisfactory in the prevention and treatment of complications and the overall therapeutic effect of diabetic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition containing insulin sensibilizer and B-family vatamines
  • Medicine composition containing insulin sensibilizer and B-family vatamines
  • Medicine composition containing insulin sensibilizer and B-family vatamines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1. The preventive and therapeutic effects of rosiglitazone maleate and folic acid in combination in rats with diabetic nephropathy.

[0036] 100 Wistar male rats, 15 were taken as normal control group, and the remaining 85 rats were intraperitoneally (ip) injected with complete Freund’s adjuvant (CFA) and small dose of streptozotocin (STZ 30mg / kg), once a week , For 2 consecutive weeks, copy the diabetes model, and end the model building in the 4th week. The model was successfully selected (fasting blood glucose between 16.8 and 25mmol / L) rats were randomly divided into model group, rosiglitazone group (0.4mg / kg), folic acid group (0.08mg / kg), rosiglitazone + Folic acid group (0.4mg / kg+0.08mg / kg), 15 rats in each group, and a normal control group. The model group and the normal group were given equal volume of normal saline, and both were given intragastrically once in the morning for 8 consecutive weeks. Urine was collected for 24 hours, and urine microalbumin (MAL...

Embodiment 2

[0046] Example 2. Preventive and therapeutic effects of pioglitazone hydrochloride and folic acid in combination on diabetic nephropathy rats.

[0047] Of 120 Wistar male rats, 15 were taken as the normal control group, and the remaining 105 were ip CFA and low-dose STZ 25mg / kg, once a week for 2 consecutive weeks, to replicate the diabetic model, and the model was completed in the fourth week. The model was successfully selected (fasting blood glucose value ≥ 11.1mmol / L) rats were randomly divided into model group, pioglitazone group (3mg / kg), folic acid group (0.5mg / kg), pioglitazone + folic acid group (3mg / kg+0.04mg) / kg), 15 rats in each group of pioglitazone + folic acid (3mg / kg+0.5mg / kg), and a normal control group. The model group and the normal group were given equal volume of normal saline for 8 weeks. Urine was collected for 24 hours, and urine MALB and α1-MG were measured. Orbital blood was collected to measure blood glucose, serum ET, NO levels, SOD and MDA levels.

[...

Embodiment 3

[0057] Example 3. Preventive and therapeutic effects of pioglitazone hydrochloride combined with vitamin B12 on rats with diabetic nephropathy.

[0058] There are 120 Wistar male rats, and 15 of them are taken as normal control group. The experimental method is the same as that in Example 2. The model was selected successfully (fasting blood glucose value ≥ 11.1mmol / L) rats were randomly divided into model group, pioglitazone group (3mg / kg), vitamin B12 group (0.2mg / kg), pioglitazone + vitamin B12 group (3mg / kg+ 0.025mg / kg), pioglitazone+vitamin B12 group (3mg / kg+0.2mg / kg) 15 rats in each group, and a normal control group. The model group and the normal group were given equal volume of normal saline for 8 weeks. Urine was collected for 24 hours, and urine MALB and urine α1-MG were measured. Orbital blood was collected to measure blood glucose, serum ET, NO, SOD and MDA levels.

[0059] Results: Compared with the normal group, the rats in the model group showed increased blood suga...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A medicinal composition used for preparing the medicines to prevent and treat hyperglycemia, diabetes, and their complications contains insulin sensitizer and B-family vitamins.

Description

Technical field [0001] The invention provides a pharmaceutical composition containing an insulin sensitizer and B vitamins, and the use of the pharmaceutical composition in the preparation of medicines. It belongs to the field of pharmacy. Background technique [0002] Diabetes is a group of metabolic diseases characterized by increased blood sugar caused by defects in insulin secretion and / or function. Diabetes patients with long-term poor blood sugar control can be accompanied by various organs, especially eye, heart, blood vessel, kidney, nerve damage, insufficiency or failure, leading to disability or premature death. In recent years, with the social and economic development of various countries in the world and the improvement of residents’ living standards, the incidence and prevalence of diabetes have increased year by year. WHO predicts that the number of patients with type 2 diabetes will be 239 million in 2010; it will break through 2025. 300 million. According to data ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/714A61K31/519A61K31/4415A61K31/425A61K9/16A61K9/20A61K9/48A61P3/10
Inventor 陈光亮王琳琳段炎炎刘海鹏李莉
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap